FDA asks panel to weigh benefit, risk of Lilly lung cancer drug
July 07, 2015 at 09:09 AM EDT
July 7 (Reuters) - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots according to a preliminary review by the U.S. Food and Drug Administration.